Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2018

Open Access 01-12-2018 | Case report

Ginkgo biloba induced mood dysregulation: a case report

Authors: Seung Sun Rho, Young Sup Woo, Won-Myong Bahk

Published in: BMC Complementary Medicine and Therapies | Issue 1/2018

Login to get access

Abstract

Background

Impairment of cognitive function as well as negative symptom is the major factor causing the decline of a patient’s functioning in chronic stages of schizophrenia. However, until now, there were no definite treatment options that could effectively reduce the impairment.

Case presentation

We report a case of mood dysregulation associated with use of Ginkgo biloba in a patient with schizophrenia. After Ginkgo biloba was given, the patient experienced cluster symptoms of mood dysregulation including irritability, difficulty in controlling anger, agitation and restlessness. We estimated the possibility as “probable” according to Naranjo scale considering circumstantial evidence.

Conclusions

This case suggests that Ginkgo biloba may have caused mood dysregulation in this patient. Although it is generally accepted as safe, more attention should be given to the adverse effect when treating with Ginkgo biloba.
Literature
1.
Millan MJ, Andrieux A, Bartzokis G, Cadenhead K, Dazzan P, Fusar-Poli P, et al. Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov. 2016;15:485–515.CrossRefPubMed
2.
Harvey PD, Koren D, Reichenberg A, Bowie CR. Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr Bull. 2006;32:250–8.CrossRefPubMed
3.
Ettinger U, Meyhofer I, Steffens M, Wagner M, Koutsouleris N. Genetics, cognition, and neurobiology of schizotypal personality: a review of the overlap with schizophrenia. Front Psychiatr. 2014;5:18.CrossRef
4.
Matza LS, Buchanan R, Purdon S, Brewster-Jordan J, Zhao Y, Revicki DA. Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment. Schizophr Bull. 2006;32:666–78.CrossRefPubMedPubMedCentral
5.
Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology. 2008;33:2061–79.CrossRefPubMed
6.
Bruno A, Pandolfo G, Crucitti M, Lorusso S, Zoccali RA, Muscatello MR. Acetyl-L-Carnitine augmentation of Clozapine in partial-responder schizophrenia: a 12-week, open-label uncontrolled preliminary study. Clin Neuropharmacol. 2016;39:277–80.CrossRefPubMed
7.
Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res. 1996;19:1–17.CrossRefPubMed
8.
Reddy RD, Yao JK. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids. 1996;55:33–43.CrossRefPubMed
9.
Wu JQ, Kosten TR, Zhang XY. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatr. 2013;46:200–6.CrossRef
10.
11.
Marcocci L, Packer L, Droy-Lefaix MT, Sekaki A, Gardes-Albert M. Antioxidant action of Ginkgo Biloba extract EGb 761. Methods Enzymol. 1994;234:462–75.CrossRefPubMed
12.
Knable MB. Extract of Ginkgo Biloba added to haloperidol was effective for positive symptoms in refractory schizophrenia. Evid Based Ment Health. 2002;5:90.CrossRefPubMed
13.
Doruk A, Uzun O, Ozsahin A. A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2008;23:223–7.CrossRefPubMed
14.
Chen X, Hong Y, Zheng P. Efficacy and safety of extract of Ginkgo Biloba as an adjunct therapy in chronic schizophrenia: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Psychiatry Res. 2015;228:121–7.CrossRefPubMed
15.
Huguet F, Drieu K, Piriou A. Decreased cerebral 5-HT1A receptors during ageing: reversal by Ginkgo Biloba extract (EGb 761). J Pharm Pharmacol. 1994;46:316–8.CrossRefPubMed
16.
Bolanos-Jimenez F, Manhaes de Castro R, Sarhan H, Prudhomme N, Drieu K, Fillion G. Stress-induced 5-HT1A receptor desensitization: protective effects of Ginkgo Biloba extract (EGb 761). Fundam Clin Pharmacol. 1995;9:169–74.CrossRefPubMed
17.
White HL, Scates PW, Cooper BR. Extracts of Ginkgo Biloba leaves inhibit monoamine oxidase. Life Sci. 1996;58:1315–21.CrossRefPubMed
18.
Fowler JS, Wang GJ, Volkow ND, Logan J, Franceschi D, Franceschi M, et al. Evidence that gingko biloba extract does not inhibit MAO a and B in living human brain. Life Sci. 2000;66:Pl141–6.CrossRefPubMed
19.
Huguet F, Tarrade T. Alpha 2-adrenoceptor changes during cerebral ageing. The effect of Ginkgo Biloba extract. J Pharm Pharmacol. 1992;44:24–7.CrossRefPubMed
20.
Amri H, Ogwuegbu SO, Boujrad N, Drieu K, Papadopoulos V. In vivo regulation of peripheral-type benzodiazepine receptor and glucocorticoid synthesis by Ginkgo Biloba extract EGb 761 and isolated ginkgolides. Endocrinology. 1996;137:5707–18.CrossRefPubMed
21.
Amri H, Drieu K, Papadopoulos V. Ex vivo regulation of adrenal cortical cell steroid and protein synthesis, in response to adrenocorticotropic hormone stimulation, by the Ginkgo Biloba extract EGb 761 and isolated ginkgolide B. Endocrinology. 1997;138:5415–26.CrossRefPubMed
22.
Marcilhac A, Dakine N, Bourhim N, Guillaume V, Grino M, Drieu K, et al. Effect of chronic administration of Ginkgo Biloba extract or Ginkgolide on the hypothalamic-pituitary-adrenal axis in the rat. Life Sci. 1998;62:2329–40.CrossRefPubMed
23.
Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res. 1999;33:181–214.CrossRefPubMed
24.
Spinella M, Eaton LA. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Inj. 2002;16:359–67.CrossRefPubMed
25.
26.
Lingaerde O, Føreland AR, Magnusson A. Can winter depression be prevented by Ginkgo Biloba extract? A placebo-controlled trial. Acta Psychiatr Scand. 1999;100:62–6.CrossRefPubMed
27.
Bachinskaya N, Hoerr R, Ihl R. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo Biloba extract EGb 761. Findings from a randomized controlled trial. Neuropsychiatr Dis Treat. 2011;7:209–15.PubMedPubMedCentral
28.
Scripnikov A, Khomenko A, Napryeyenko O. Effects of Ginkgo Biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. Wien Med Wochenschr. 2007;157:295–300.CrossRefPubMed
29.
DeFeudis FV, Drieu K. Ginkgo Biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets. 2000;1:25–58.CrossRefPubMed
30.
Heinonen T, Gaus W. Cross matching observations on toxicological and clinical data for the assessment of tolerability and safety of Ginkgo Biloba leaf extract. Toxicology. 2015;327:95–115.CrossRefPubMed
31.
Reininghaus U, Priebe S. Measuring patient-reported outcomes in psychosis: conceptual and methodological review. Br J Psychiatry. 2012;201:262–7.CrossRefPubMed
32.
Takeuchi H, Fervaha G, Remington G. Reliability of a patient-reported outcome measure in schizophrenia: results from back-to-back self-ratings. Psychiatry Res. 2016;244:415–9.CrossRefPubMed
33.
Hamera EK, Schneider JK, Potocky M, Casebeer MA. Validity of self-administered symptom scales in clients with schizophrenia and schizoaffective disorders. Schizophr Res. 1996;19:213–9.CrossRefPubMed
34.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRefPubMed
35.
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255–9.CrossRefPubMed
Metadata
Title
Ginkgo biloba induced mood dysregulation: a case report
Authors
Seung Sun Rho
Young Sup Woo
Won-Myong Bahk
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2018
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-018-2081-4

Other articles of this Issue 1/2018

BMC Complementary Medicine and Therapies 1/2018 Go to the issue

Research article

Antrodia cinnamomea extract inhibits the proliferation of tamoxifen-resistant breast cancer cells through apoptosis and skp2/microRNAs pathway

Research article

The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews

Research article

Adenosine and adenosine-5′-monophosphate ingestion ameliorates abnormal glucose metabolism in mice fed a high-fat diet

Research article

Urox containing concentrated extracts of Crataeva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root, in the treatment of symptoms of overactive bladder and urinary incontinence: a phase 2, randomised, double-blind placebo controlled trial

Research article

Beneficial effect of compound essential oil inhalation on central fatigue

Research article

Characteristics and status of Korean medicine use in whiplash-associated disorder patients